logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.

    Article - En anglais

    Background Identification of economical interventions to decrease HIV-1 transmission to children is an urgent public-health priority in sub-Saharan Africa.

    We assessed the cost effectiveness of the HIVNET 012 nevirapine regimen.

    Methods We assessed cost effectiveness in a hypothetical cohort of 20000 pregnant women in sub-Saharan Africa.

    Our main outcome measures were programme cost, paediatric HIV-1 cases averted, cost per case averted, and cost per disability-adjusted life-year (DALY).

    We compared HIVNET 012 with other short-course antiretroviral regimens.

    We also compared two implementation strategies : counselling and HIV-1 testing before treatment (targeted treatment), or nevirapine for all pregnant women (universal treatment, no counselling and testing).

    We did univariate and multivariate sensitivity analyses.

    Findings For universal treatment with 30% HIV-1 seroprevalence, the HIVNET 012 regimen would avert 603 cases of HIV-1 in babies, cost US$83 333, and generate 15862 DALYs.

    The associated cost-effectiveness ratios were $138 per case averted or $5.25 per DALY.

    At 15% seroprevalence, the universal treatment option would cost $83 333 and avert 302 cases at $276 per case averted or $10.51 per DALY.

    For targeted treatment at 30% seroprevalence, HIVNET 012 would cost $141 922 and avert 476 cases at $298 per case averted or $11.29 per DALY. (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Transmission verticale, Névirapine, Antiviral, Chimioprophylaxie, Traitement, Prévention, Inhibiteur enzyme, RNA-directed DNA polymerase, Nucleotidyltransferases, Transferases, Enzyme, Dose unique, Analyse coût efficacité, Homme, Femelle, Gestation, Nouveau né, Economie santé, Afrique subsaharienne, Afrique, Immunopathologie, Immunodéficit, Gestation pathologie, Nouveau né pathologie

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Vertical transmission, Nevirapine, Antiviral, Chemoprophylaxis, Treatment, Prevention, Enzyme inhibitor, RNA-directed DNA polymerase, Nucleotidyltransferases, Transferases, Enzyme, Single dose, Cost efficiency analysis, Human, Female, Pregnancy, Newborn, Health economy, Sub-Saharan Africa, Africa, Immunopathology, Immune deficiency, Pregnancy disorders, Newborn diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0450902

    Code Inist : 002B02S05. Création : 22/03/2000.